Suppression of TDP-43 aggregation by artificial peptide binder targeting to its low complexity domain

Biochem Biophys Res Commun. 2023 Jun 25:662:119-125. doi: 10.1016/j.bbrc.2023.04.064. Epub 2023 Apr 20.

Abstract

TAR DNA-binding protein 43 (TDP-43), aggregation prone protein, is a potential target of drug discovery for amyotrophic lateral sclerosis. The molecular binders, targeting the disordered low complexity domain (LCD) relevant to the aggregation, may suppress the aggregation. Recently, Kamagata et al. developed a rational design of peptide binders targeting intrinsically disordered proteins based on contact energies between residue pairs. In this study, we designed 18 producible peptide binder candidates to TDP-43 LCD by using this method. Fluorescence anisotropy titration and surface plasmon resonance assays demonstrated that one of the designed peptides bound to TDP-43 LCD at 30 μM. Thioflavin-T fluorescence and sedimentation assays showed that the peptide binder suppressed the aggregation of TDP-43. In summary, this study highlights the potential applicability of peptide binder design for aggregation prone proteins.

Publication types

  • Research Support, Non-U.S. Gov't

MeSH terms

  • Amyotrophic Lateral Sclerosis* / metabolism
  • DNA-Binding Proteins / metabolism
  • Humans
  • Intrinsically Disordered Proteins*
  • Peptides / pharmacology

Substances

  • Peptides
  • Intrinsically Disordered Proteins
  • DNA-Binding Proteins